Document:

EX-10.3

 Exhibit 10.3 

Execution Version 

IDEAYA BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

January 31, 2018 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	1.	  	Registration Rights	  	 	1	 
		  	1.1	  	Definitions	  	 	1	 
		  	1.2	  	Request for Registration	  	 	3	 
		  	1.3	  	Company Registration	  	 	4	 
		  	1.4	  	Obligations of the Company	  	 	5	 
		  	1.5	  	Furnish Information	  	 	7	 
		  	1.6	  	Expenses of Registration	  	 	7	 
		  	1.7	  	Delay of Registration	  	 	8	 
		  	1.8	  	Indemnification	  	 	8	 
		  	1.9	  	Reports Under Exchange Act	  	 	10	 
		  	1.10	  	Form S-3 Registration	  	 	11	 
		  	1.11	  	Assignment of Registration Rights	  	 	11	 
		  	1.12	  	Termination of Registration Rights	  	 	12	 
		  	1.13	  	Limitations on Subsequent Registration Rights	  	 	12	 
			
	2.	  	Market Stand-Off Agreement	  	 	12	 
			
	3.	  	Covenants of the Company	  	 	13	 
		  	3.1	  	Delivery of Financial Statements	  	 	13	 
		  	3.2	  	Inspection	  	 	14	 
		  	3.3	  	Right of First Offer	  	 	14	 
		  	3.4	  	Confidential Information and Invention Assignment Agreements	  	 	15	 
		  	3.5	  	Indemnification	  	 	15	 
		  	3.6	  	Directors’ & Officers’ Liability	  	 	15	 
		  	3.7	  	Board Matters	  	 	16	 
		  	3.8	  	Stock Vesting	  	 	16	 
		  	3.9	  	Observer Rights	  	 	16	 
		  	3.10	  	Confidentiality	  	 	17	 
		  	3.11	  	Subsidiaries	  	 	18	 
		  	3.12	  	Indemnification Matters	  	 	18	 
		  	3.13	  	Termination of Covenants	  	 	18	 
			
	4.	  	Restrictions on Transferability of Securities; Compliance with Securities Act	  	 	19	 
		  	4.1	  	Restrictions on Transferability	  	 	19	 
		  	4.2	  	Notice of Proposed Transfers	  	 	19	 
			
	5.	  	Miscellaneous	  	 	20	 
		  	5.1	  	Successors and Assigns	  	 	20	 
		  	5.2	  	Governing Law	  	 	20	 
		  	5.3	  	Venue	  	 	20	 
		  	5.4	  	Counterparts	  	 	20	 
		  	5.5	  	Titles and Subtitles	  	 	20	 
		  	5.6	  	Notices	  	 	20	 
		  	5.7	  	Amendments and Waivers; Termination	  	 	21	 

  
 i 

									
		  	5.8	  	Severability	  	 	21	 
		  	5.9	  	Right to Invest	  	 	21	 
		  	5.10	  	Additional Parties	  	 	22	 
		  	5.11	  	Delays or Omissions	  	 	22	 
		  	5.12	  	Aggregation of Stock	  	 	22	 
		  	5.13	  	Electronic and Facsimile Signatures	  	 	22	 
		  	5.14	  	Entire Agreement	  	 	22	 
		  	5.15	  	Advice of Counsel	  	 	22	 

									
			
	Schedule A	  	Schedule of Investors	  			

  

  
 ii 

 Execution Version 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of January 31, 2018, by
and among Ideaya Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”).

 WHEREAS, the Company and certain of the Investors (the “Existing Investors”) are parties to that certain
Investors’ Rights Agreement, dated March 1, 2016 (the “Prior Agreement”). 
 WHEREAS, pursuant to
Section 5.7 of the Prior Agreement and subject to certain specified exceptions, any term of the Prior Agreement may be amended and the observance of any term of the Prior Agreement may be waived (either generally or in a particular instance,
and either retroactively or prospectively) with the written consent of the Company and the holders of at least 60% of the Registrable Securities (as defined in the Prior Agreement) then-outstanding (the “Requisite Existing
Investors”). 
 WHEREAS, the Company and certain of the Investors (the “Participating Investors”) are
parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith (as may be amended from time to time, the “Purchase Agreement”). 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Participating Investors to invest funds
in the Company pursuant to the Purchase Agreement, the Company and the undersigned Existing Investors, constituting the Requisite Existing Investors, desire to amend and restate and supersede the Prior Agreement in its entirety as set forth herein
and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement. 
 NOW,
THEREFORE, the parties hereto hereby agree as follows: 
 1. Registration Rights. The Company covenants and agrees as follows:

 1.1 Definitions. For purposes of this Agreement: 

(a) “Acquisition” means a Liquidation (as defined in the Restated Certificate). 

(b) “Affiliate” as used in this Agreement shall have the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations under the Exchange Act (as defined below). 
 (c)
“Board” means the Board of Directors of the Company. 
 (d) “Common Stock” means shares of the
Company’s common stock, par value $0.0001 per share. 

 (e) “Convertible Securities” means any bonds, debentures, notes or other
evidences of indebtedness, and any options, warrants, shares (including, but not limited to, shares of Preferred Stock) purchase rights or any other securities convertible into, exercisable for, or exchangeable for Common Stock. 

(f) “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar successor federal statute, and the
rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (g) “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC (as defined below) that permits
inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 (h)
“Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.11 of this Agreement. 

(i) “Initiating Holders” means any Holder or Holders who in the aggregate hold at least 65% of the Registrable Securities
then-outstanding. 
 (j) “IPO” means an initial public offering of the Common Stock of the Company to the general public
that is effected pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act in connection with which all outstanding shares of Preferred Stock will be converted to Common Stock. 

(k) “Preferred Stock” means the Series A Preferred Stock and the Series B Preferred Stock. 

(l) The terms “register,” “registered” and “registration” refer to a registration effected
by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(m) “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock and
(ii) any Common Stock of the Company issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to or in exchange for or in replacement of the
shares referenced in clause (i) above; provided, however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they (A) have not been sold to or through a broker or dealer
or underwriter in a public distribution or a public securities transaction, (B) have not been transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with Section 1.11
hereof or (C) with respect to each Holder, all such shares or other securities held by such Holder have become eligible for sale under Rule 144 (as defined below) (or any similar or successor rule) during any single ninety (90) day period.

  
 2 

 (n) The number of shares of “Registrable Securities then-outstanding”
shall be the sum of the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then outstanding Convertible Securities that are, Registrable Securities. 

(o) “Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as filed with the
Secretary of State of Delaware on or about the date hereof, as amended from time to time. 
 (p) “Restricted Securities”
means the securities of the Company required to bear the legends set forth in Section 3.6 of that certain Series A Preferred Stock Purchase Agreement, dated as of March 1, 2016, or Section 3.6 of the Purchase Agreement. 

(q) “Rule 144” means Rule 144 as promulgated by the SEC under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the SEC. 
 (r) “SEC” shall mean the Securities and
Exchange Commission. 
 (s) “Securities Act” means the Securities Act of 1933, as amended, or any similar successor
federal statute, and the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (t) “Series A
Preferred Stock” means the Series A Preferred Stock of the Company, par value $0.0001 per share. 
 (u) “Series B
Preferred Stock” means the Series B Preferred Stock of the Company, par value $0.0001 per share. 
 1.2 Request for
Registration. 
 (a) Subject to the conditions of this Section 1.2, if the Company shall receive at any time
after the earlier of (i) January 31, 2023 or (ii) six months following the IPO, a written request from the Initiating Holders that the Company file a registration statement under the Securities Act covering the registration of
Registrable Securities which would have an aggregate offering price of not less than $10,000,000, then the Company shall within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the
limitations of this Section 1.2, use commercially reasonable efforts to effect, as soon as practicable, the registration under the Securities Act of all Registrable Securities that the Holders request to be registered in a
written request received by the Company within twenty (20) days of the mailing of the Company’s notice pursuant to this Section 1.2(a). 

(b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they
shall so advise the Company as a part of their request made pursuant to Section 1.2(a) and the Company shall include such information in the written notice referred to in Section 1.2(a). The
underwriter will be selected by the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute 

  
 3 

 
their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any
other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated, first, to the Initiating Holders and each Investor that
participated in the underwriting as a Holder on a pro rata basis based on the total number of Registrable Securities held by the Initiating Holders and participating Investors; and second, to the other Holders on a pro rata basis among
all such other Holders. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to the Holders requesting a registration
statement pursuant to this Section 1.2 a certificate signed by the President and/or Chief Executive Officer of the Company stating that, in the good faith judgment of the Board, it would be materially detrimental to the
Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer taking action with respect to such filing for a
period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve (12) month period. 

(d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this
Section 1.2: 
 (i) after the Company has effected two (2) registrations pursuant to this
Section 1.2 and such registrations have been declared or ordered effective; 
 (ii) during the six-month period following the effective date of the registration statement pertaining to an IPO; 

(iii) if, within thirty (30) days of a registration request by the Initiating Holders, the Company gives notice to the Holders of its
intent to file or confidentially submit a registration statement for an IPO within ninety (90) days; or 
 (iv) if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.10 below. 

1.3 Company Registration. 

(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of
securities to participants in a Company stock plan, registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or
a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities 

  
 4 

 
which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty
(20) days after mailing of such notice by the Company in accordance with Section 5.6, the Company shall, subject to the provisions of Section 1.3(b), cause to be registered under the Securities Act all of
the Registrable Securities that each such Holder has requested to be registered. Registrations effected pursuant to this Section 1.3 shall not be counted as demands for registration pursuant to
Section 1.2. 
 (b) If the registration statement under which the Company gives notice under this
Section 1.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to be included in a registration pursuant to this
Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other
provision of the Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first,
to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis. No such
reduction shall reduce the amount of securities of the selling Holders included in the registration below thirty percent (30%) of the total amount of securities included in such registration, unless such offering is the IPO and such registration
does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding sentence. For any Holder that is a partnership or
corporation, the partners, retired partners and shareholders of such Holder, or the estates and lineal descendants of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a
single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such
“Holder,” as defined in this sentence. 
 (c) The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

1.4 Obligations of the Company. Whenever required under this Section 1 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of 65% of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that 120 day period shall be extended for a period
of time equal to the period the Holders refrain, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration. 

  
 5 

 (b) Prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

(c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue
sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process, or subject itself to general taxation, in any such states or jurisdictions. 
 (e) In the event of any underwritten
public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform
its obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act or the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or nationally recognized
quotation system on which similar securities issued by the Company are then listed. 
 (h) Provide a transfer agent and registrar for all
Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i) Reasonably cooperate in all necessary respects with (A) counsel in preparation of the customary legal opinions and
(B) accountants in preparation of the customary comfort letters, copies of which shall be provided to each Holder so requesting; provided that the Holders shall not be entitled to rely upon such legal opinions and comfort letters other
than in accordance with their own respective terms. 

  
 6 

 (j) Make available for inspection by the selling Holders, any underwriter(s) participating
in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and
properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as
necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith, provided that any information obtained pursuant to this subsection (j) shall be
subject to the confidentiality and non-use obligations of Section 3.10 of this Agreement, and the selling Holders shall be responsible for any breach thereof by any underwriter or other agent of such
selling Holder. 
 (k) After such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 1.5 Furnish Information. 

(a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. 
 (b) The
Company shall have no obligation with respect to any registration requested pursuant to Section 1.10 if, due to the operation of Section 1.5(a), the number of shares of the Registrable Securities
to be included in the registration does not equal or exceed the number of shares required to originally trigger the Company’s obligation to initiate such registration as specified in Section 1.10(b). 

1.6 Expenses of Registration. All expenses (other than underwriting discounts and commissions, stock transfer taxes and fees of counsel
to the selling shareholders (except as set forth below)) incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, Section 1.3 and Section 1.10, including
(without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders (not to
exceed $35,000), shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2(a) or
Section 1.10 if the registration request is subsequently withdrawn at the request of the Holders of at least 65% of the Registrable Securities to be registered (in which case all participating Holders shall bear such
expenses pro rata based upon the number of Registrable Securities that were to be registered in the withdrawn registration) unless such Holders agree to forfeit their right to one registration pursuant to
Section 1.2(a) or Section 1.10, as the case may be; provided, however, that if at the time of such withdrawal, the Holders (i) have learned of a material adverse change in the
condition, business, or prospects of the Company that was not known at the time of their requestor could have not been reasonably known given the prior communication or information provided by the Company to the Holders and (ii) have withdrawn
the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to
Section 1.2(a) or Section 1.10. 

  
 7 

 1.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.8 Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any
underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint
or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the
Company will pay to each such Holder, underwriter or controlling person any legal or other expenses reasonably incurred, as incurred, by them in connection with investigating or defending any such loss, claim, damage, liability or action;
provided, however, that the indemnity agreement contained in this Section 1.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of
or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for inclusion in a registration statement in connection with such registration by such Holder, underwriter or controlling
person and; provided further, however, that the foregoing indemnity agreement with respect to any preliminary prospectus shall not inure to the benefit of any Holder or underwriter, or any person controlling such Holder or underwriter, from
whom the person asserting any such losses, claims, damages or liabilities purchased shares in the offering, if a copy of the prospectus (as then amended or supplemented) was not sent or given by or on behalf of such Holder or underwriter to such
person, if required by law so to have been delivered by such Holder, at or prior to the written confirmation of the sale of the shares to such person, and if the prospectus (as so amended or supplemented) would have cured the defect giving rise to
such loss, claim, damage or liability. 
 (b) To the extent permitted by law, each Holder selling Registrable Securities in a registration
under this Agreement, severally and not jointly, will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of
the 

  
 8 

 
Securities Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such
underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay any legal or other expenses reasonably incurred, as incurred, by any person intended to be indemnified pursuant to this
Section 1.8(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this
Section 1.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably
withheld, conditioned or delayed, provided that in no event shall any indemnity under this Section 1.8(b) plus any contribution under this Section 1.8 exceed the net proceeds from the
offering received by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 1.8 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.8, deliver to the
indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to
assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that prior to assuming control of such defense, the indemnifying party must acknowledge that, if the facts as alleged by the claimant in such
claim are true, it would have an indemnity obligation for the expenses, losses, claims, damages and liabilities resulting from such claim as provided hereunder and must furnish the indemnified party with reasonable evidence that the indemnifying
party has adequate resources to defend such claim and fulfill its indemnity obligations hereunder; and the indemnifying party shall not be entitled to assume or maintain control of the defense of any claim and shall pay the fees and expenses of one
counsel retained by the indemnified party if (i) the indemnifying party does not deliver the acknowledgment referred to above within thirty (30) days of receipt of notice of the claim, (ii) the claim relates to or arises in connection
with any criminal proceeding, action, indictment or allegation, (iii) the indemnified party reasonably believes an adverse determination with respect to the claim would be detrimental to the reputation or future business prospects of the
indemnified party or any of its affiliates, (iv) the claim seeks an injunction or equitable relief against the indemnified party or any of its affiliates or (v) the indemnifying party has failed or is failing to prosecute or defend
vigorously the claim; provided, further, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the
fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified
party and any other party represented by such counsel in such proceeding. The failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under this Agreement, except to the extent
that the indemnifying party’s ability to defend against such claim or litigation is materially impaired as a result of such failure to give notice. No indemnifying 

  
 9 

 
party in the defense of any such claim or litigation shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement that does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation (which consent shall not be unreasonably withheld, conditioned or delayed), and
no indemnified party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of the indemnifying party (which consent shall not be unreasonably withheld, conditioned or delayed). 

(d) If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided that in no event shall any contribution under this
Section 1.8(d) when combined with any payment made pursuant to Section 1.8(b) hereunder by a Holder exceed the net proceeds from the offering received by such Holder. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by
the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1 and otherwise
shall survive the termination of this Agreement. 
 1.9 Reports Under Exchange Act. With a view to making available to the Holders
the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company agrees to: 
 (a) make and keep public information available, as those terms are
understood and defined in Rule 144, at all times after ninety (90) days after the effective date of the IPO; 
 (b) file with the SEC
in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

  
 10 

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company),
the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at
any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested in availing
any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

1.10 Form S-3 Registration. In case the Company shall receive from the Initiating Holders, a
written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Initiating
Holder or Holders, the Company will: 
 (a) promptly give written notice of the proposed registration, and any related qualification or
compliance, to all other Holders; and 
 (b) use reasonable efforts to effect such registration and all such qualifications and compliances
as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of
the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the
Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.10: (i) if Form S-3 is not available for such offering by the
Initiating Holders; (ii) if the Initiating Holders propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $5,000,000;
(iii) after the Company has effected two (2) registrations pursuant to this Section 1.10 in any twelve (12) month period and such registrations have been declared or ordered effective; (iv) if the Company
shall furnish to the Initiating Holders a certificate signed by the President and/or Chief Executive Officer of the Company stating that in the good faith judgment of the Board, it would be materially detrimental to the Company and its stockholders
for such Form S-3 registration to be filed at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a
period of not more than ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.10; provided, however, that the Company shall not utilize this right more than once in any
twelve (12) month period; or (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or
compliance or otherwise subject itself to general taxation. Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after
receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.10 shall not be counted as demands for registration effected pursuant to Section 1.2. 

1.11 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be assigned (but only with all related obligations) by (i) a Holder that is a partnership, to any subsidiary, parent, partner, retired partner or affiliated fund of such Holder, (ii) a Holder that is
a limited liability company, to any member 

  
 11 

 
or former member of such Holder, (iii) a Holder who is an individual, to such Holder’s family member or trust for the benefit of such Holder or such Holder’s family member,
(iv) a Major Investor (as defined in Section 3.3) to an Affiliate or (v) a Holder to any other person acquiring at least 1,000,000 shares of Registrable Securities (as appropriately adjusted for any stock split,
dividend, combination or other recapitalization or like transactions) (or all of such transferring Holder’s shares if less); provided (in all cases) that (a) the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the
terms and conditions of this Agreement, including without limitation the provisions of Section 2 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of
such securities by the transferee or assignee is restricted under the Securities Act. 
 1.12 Termination of Registration Rights. No
Holder shall be entitled to exercise any right provided for in this Section 1 after the earliest to occur of the following: (i) the third anniversary of the effective date of the IPO, (ii) the date when all
Registrable Securities held by such Holder can be sold in any ninety (90) day period without registration in compliance with Rule 144 or (iii) upon the consummation of an Acquisition. 

1.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of at least 65% of the Registrable Securities then-outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder to
include such securities in any registration filed under Sections 1.2 or 1.3 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent
that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included. 
 2.
Market Stand-Off Agreement. Each Holder hereby agrees that in connection with an IPO, such Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into
any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act in connection with the
Company’s IPO (the “Stand-Off Period”) as long as all stockholders individually owning more than one percent (1%) of the Company’s then outstanding shares of Common Stock (after
giving effect to conversion into Common Stock of all outstanding shares of Preferred Stock) and all executive officers and directors enter into similar agreements. Each Holder agrees to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The underwriters of the Company’s stock are intended third-party beneficiaries of this Section 2 and
shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall
apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

  
 12 

 3. Covenants of the Company. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor (as defined in
Section 3.3): 
 (a) as soon as practicable, but in any event within one hundred twenty (120) days after the
end of each fiscal year of the Company (or such other time that the Board unanimously approves), an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such fiscal year,
and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable detail and prepared in accordance with generally accepted accounting principles
(“GAAP”), and audited and certified by an independent public accounting firm selected with the approval of the Board; 

(b) as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (or
such other time that the Board unanimously approves), a comparison of the Company’s audited financial statements and results of operations against the Company’s annual budget from such fiscal year, setting forth in reasonable detail the
variances between the actual results of operations and budgeted or forecasted results; 
 (c) as soon as practicable, but in any event
within forty five (45) days after the end of each quarter of each fiscal year of the Company, an unaudited income statement, an unaudited statement of cash flows for such fiscal quarter and an unaudited balance sheet for such quarter, such
quarterly financial reports to be in reasonable detail; 
 (d) as soon as practicable after the end of each calendar month, and in any
event within thirty (30) days thereafter, an unaudited income statement, an unaudited statement of cash flows for such month, and an unaudited balance sheet for such month, such monthly financial reports to be in reasonable detail; 

(e) as soon as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year, a budget for the next
fiscal year, including balance sheets, income statements and statements of cash flows, such budget to be in reasonable detail and prepared on a monthly basis; and 

(f) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of such quarter, the Common Stock issuable upon conversion
or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company. 

  
 13 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

3.2 Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the
Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be convenient to the Company and such Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information which it reasonably considers to be a trade secret or similar confidential information.

 3.3 Right of First Offer. 

(a) Subject to the terms and conditions specified in this Section 3.3, the Company hereby grants to each Investor,
for so long as an Investor holds at least 1,000,000 shares of Common Stock issued or issuable upon conversion of the Preferred Stock (as appropriately adjusted for any stock split, dividend, combination or other recapitalization or like transaction)
(such Investor, a “Major Investor”), the right of first offer with respect to future issuances by the Company of its Shares (as hereinafter defined). A Major Investor shall be entitled to apportion the right of first offer hereby
granted it among itself and its partners and Affiliates in such proportions as it deems appropriate. Each time following the date hereof that the Company proposes to offer or issue any shares of any class of its capital stock or any Convertible
Securities (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions. The Company shall deliver a notice in accordance with
Section 5.6 to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered and (iii) the price and terms upon which it proposes to offer
such Shares. If any prospective purchaser has offered to pay for any Shares with property, services or any other non-cash consideration, then the Major Investors shall nevertheless have the right to pay for
such Shares with cash in an amount equal to the fair market value of the non-cash consideration offered by the prospective purchaser, where the fair market value of such
non-cash consideration shall be conclusively determined in good faith by the Board. 
 (b) By
written notification received by the Company, within twenty (20) calendar days after delivery of the notice, the Major Investor may elect to purchase, at the price and on the terms specified in the notice, up to that portion of such Shares that
equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by such Major Investor bears to the total number of shares of Common Stock of the Company then-outstanding
(assuming full conversion of all outstanding convertible securities). The Company shall promptly, in writing, inform each Major Investor that elects to purchase all the shares available to it (a “Fully-Exercising Investor”) of any
other Major Investor’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to purchase that portion of the Shares for which Major Investor were
entitled to subscribe but which were not subscribed for that is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears to
the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares. 

  
 14 

 (c) If all Shares that Major Investors are entitled to purchase pursuant to
Section 3.3(b) are not elected to be purchased as provided in Section 3.3(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in
Section 3.3(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the notice. If the
Company does not enter into a definitive binding agreement for the sale of the Shares within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder shall be deemed to
be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
 (d) The right of
first offer in this Section 3.3 shall not be applicable to the Exempted Securities (as defined in the Restated Certificate). 

(e) Notwithstanding the foregoing, the right of first offer in this Section 3.3 shall not be applicable to any
Major Investor with respect to any subsequent issuance of Shares if: (i) at the time of such subsequent issuance of Shares, such Major Investor is not an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act and (ii) such subsequent issuance of Shares is otherwise being offered only to accredited investors as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

3.4 Confidential Information and Invention Assignment Agreements. The Company shall require all employees to execute and deliver a
confidential information and invention assignment agreement substantially in a form approved by the Board. The Company shall require all directors, consultants and independent contractors to the Company that have had access to the Company’s
intellectual property to enter into an agreement containing appropriate confidentiality and invention assignment provisions. 
 3.5
Indemnification. The Company shall use its reasonable efforts to provide that its Restated Certificate and bylaws provide for indemnification of officers and directors of the Company to the maximum extent permitted by law. If the Company or
any of its successors or assignees consolidates with or merges into any other entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that
the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 3.6 Directors’ & Officers’ Liability.
The Company shall use commercially reasonable efforts to obtain from financially sound and reputable insurers, and thereafter maintain, a policy or policies of directors’ and officers’ liability insurance on terms and conditions
satisfactory to the Board, including a majority of then-serving Preferred Directors, and with a coverage limit of not less than $2,000,000, and will use commercially reasonable efforts to cause such policy to be maintained until such time as the
Board, including the approval of a majority of the then-serving Preferred Directors, determines that such insurance should be discontinued or otherwise modified. 

  
 15 

 3.7 Board Matters. Upon request, the Company shall promptly reimburse in full, each
Observer (as defined below) and non-employee director of the Company for his or her reasonable and documented out-of-pocket
expenses incurred in connection with the attendance of meetings of the Board or any committee thereof or in the course of pre-approved business conducted on behalf of the Company. 

3.8 Stock Vesting. Unless otherwise approved by the Board, including the approval of a majority of the then-serving Preferred
Directors, all stock, stock options and other stock equivalents issued after the date of this Agreement to employees shall be subject to vesting no earlier than as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of
the first year following the earlier of the date of issuance or such person’s services commencement date with the Company and (b) seventy-five percent (75%) of such stock shall vest in equal monthly installments over the remaining three
(3) years. With respect to any shares of stock purchased by any such person still subject to vesting, the Company’s repurchase option shall provide that upon such person’s termination of employment or service with the Company, with or
without cause, the Company or its assignee shall have the option to purchase at cost any unvested shares of stock held by such person. No stock option, restricted stock and similar equity grant issued to officers and consultants shall be
transferable until such time as such stock option, restricted stock and similar equity grant is fully vested. No stock option shall have a maximum term of more than ten (10) years. 

3.9 Observer Rights. The Company covenants and agrees with each of 5AM Ventures (as defined below), Canaan X L.P., Celgene Corporation
(“Celgene”), Roche Finance Ltd (“Roche”) and BVF Partners LP (each, together with their respective Affiliates, an “Investor with Observer Rights”) that, for so long as such Investor with Observer
Rights is a Major Investor, such Investor with Observer Rights shall be entitled to designate one observer (each, an “Observer” and together, the “Observers”) to attend all meetings of the Board, including
telephonic meetings, and the Company will give each Observer notice of such meetings, by telecopy or by such other means as such notices are delivered to the members of the Board, not later than the same time notice is provided or delivered to the
Board; provided that the Observer agrees to hold in confidence all information regarding the Company provided to such Observer acting in such capacity; and provided further that the Observer may be excluded from any meeting or portion
thereof and the Company reserves the right to withhold any information from such Observer if the Company reasonably believes that such withholding of information or exclusion is reasonably necessary to preserve the attorney-client privilege, to
protect highly confidential proprietary information, if the Board determines in good faith that there exists, with respect to the subject of such deliberation or of such Board materials, an actual or potential conflict of interest between the
Observer or the Investor with Observer Rights that designated such Observer and the Company, or for other similar reasons. As used herein, “5AM Ventures” means 5AM Ventures IV, L.P. and 5AM
Co-Investors IV, L.P., collectively. 

  
 16 

 3.10 Confidentiality. Each Investor agrees, severally and not jointly, to use the
same degree of care as such Investor uses to protect its own confidential information for any information obtained pursuant to Section 3.1, Section 3.2 and Section 3.9
hereof and such Investor acknowledges that it will not, without the prior written consent of the Company, disclose, divulge or use for any purpose (other than to monitor its investment in the Company) such information without the prior written
consent of the Company except such information that (a) was in the public domain prior to the time it was furnished to such Investor, (b) is or becomes (through no breach of this Section 3.10 or any other
contractual obligation of confidentiality by such Investor) generally available to the public, (c) was in the possession of, or known by, such Investor prior to receipt from the Company without a breach of any obligation of confidentiality
known to such Investor to be owed to the Company, (d) was made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company or (e) was independently
developed without any use of the Company’s confidential information. Notwithstanding the foregoing, (i) each Investor that is a limited partnership or limited liability company may disclose such information to (x) any former partners
or members who retained an economic interest in such Investor or (y) any current or prospective partner of the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management
company of such Investor (or any employee or representative of any of the foregoing); (ii) each Investor that is a corporation may disclose such proprietary or confidential information to any Affiliate (or any employee or representative of any of
the foregoing); (iii) each Investor may disclose such information to the legal counsel, accountants or representatives for such Investor; and (iv) each Investor may disclose such information to any prospective purchaser of any Registrable
Securities from such Investor if such prospective purchaser executed a customary confidentiality agreement, reasonably acceptable to the Company, with such Investor; provided, however, that, notwithstanding the foregoing, no Investor shall
disclose information pursuant to subsection (iv) of this Section 3.10 unless such Investor has provided the Company with written notice thereof (including the identity of the party to whom such Investor intends to
disclose such information and the executed confidentiality agreement to which such party is subject) at least five (5) business days prior to such disclosure; and provided further, however, that in no event shall any Investor disclose
information pursuant to subsection (iv) of this Section 3.10 to any competitor of the Company. In the event that the Investor is requested by any governmental authority or required by law to disclose any information of
the Company, the Investor shall, to the extent permitted by applicable law, promptly notify the Company in writing of such request or requirement and the scope and nature of disclosure so requested or required so that the Company, at its own
expense, may seek an appropriate protective order or other remedy to protect the confidentiality of the confidential information and/or take other lawful action to protect its interests, and the Investor, at the Company’s expense, will provide
reasonable assistance to the Company in connection therewith. In the absence of a protective order or the receipt of a written waiver from the Company’s chief executive officer hereunder with respect to any such disclosure, the Investor will
disclose only that portion of the Company’s information that is requested, or as the Investor is advised by legal counsel is required, to be disclosed. Neither the Company nor any of its affiliates shall use the name of Celgene, Roche or
Novartis Institutes for Biomedical Research, Inc. (“Novartis”) or the name of any of Celgene’s, Roche’s or Novartis’ affiliates in any press release, published notice or other publication relating to such
Investor’s investment in the Company without the prior written consent of such Investor. For the avoidance of doubt, the Company may advise its tax, legal or other professional advisors, other investors and prospective investors of the fact of
the investments by Celgene, Roche and Novartis in the Company, provided that such persons are obligated to keep such information confidential, and the Company may make any other disclosure regarding the investments of Celgene, Roche and Novartis in
the Company as required by law or legal process. 

  
 17 

 3.11 Subsidiaries. The Company will not, without the approval of the Board:
(a) organize or acquire any entity that is a subsidiary unless such subsidiary is wholly owned by the Company, (b) permit any subsidiary to consolidate or merge into or with any entity or sell or transfer all or substantially all its
assets, except that the Company may permit a subsidiary to consolidate or merge into or with or sell or transfer assets to any other subsidiary or (c) sell or otherwise transfer any shares of capital stock of any subsidiary or other equity
securities of any entity, except to the Company or another subsidiary, or permit any subsidiary to issue, sell or otherwise transfer any shares of its capital stock or the capital stock of any subsidiary or other equity securities of any entity or
to sell all or substantially all of such subsidiary’s assets, except to the Company or another subsidiary. 
 3.12 Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses
and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its
obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be
required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the
extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the
Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The
Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the
Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

3.13 Termination of Covenants. Except as provided herein, the covenants set forth in this Section 3 shall
terminate immediately prior to the earlier to occur of: (a) an IPO or (b) an Acquisition. Notwithstanding the forgoing sentence, the covenants set forth in Sections 3.1 and 3.2 hereof will terminate immediately prior to the
earliest to occur of: (x) an IPO, (y) the time that the Company becomes subject to the reporting provisions of the Exchange Act, or (z) an Acquisition. 

  
 18 

 4. Restrictions on Transferability of Securities; Compliance with Securities Act.

 4.1 Restrictions on Transferability. The Restricted Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 
 4.2 Notice of Proposed Transfers. The Holder of
each certificate representing Restricted Securities by acceptance thereof agrees to comply in all respects with the provisions of this Section 4.2. 

(a) Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the
Securities Act covering the proposed transaction, the holder thereof shall give notice to the Company of such holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the
proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall,
be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory
to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to
sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any transaction in compliance
with SEC Rule 144; provided that each transferee agrees in writing to be subject to the terms of this Section 4.2. Each certificate or instrument evidencing the Restricted Securities transferred as above provided
shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 3.6 of that certain Series A Preferred Stock Purchase Agreement, dated as of March 1, 2016, or Section 3.6 of
the Purchase Agreement, as applicable, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 
 (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to a
transfer by a holder that is (A) a partnership transferring to its partners or former partners in accordance with partnership interests, (B) a corporation transferring to a wholly-owned subsidiary, Affiliate or a parent corporation that
owns all of the capital stock of the holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, (D) an entity transferring to an Affiliate or
(E) an individual transferring to the holder’s family member or trust for the benefit of an individual holder; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same
extent as if he were an original holder hereunder. 

  
 19 

 5. Miscellaneous. 

5.1 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

5.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements
among California residents entered into and to be performed entirely within California. 
 5.3 Venue. Any suit or proceeding relating
to, arising out of or arising under this Agreement shall be brought in the federal or state courts located in San Mateo County, California, United States, which courts shall have the sole and exclusive in personam, subject matter and other
jurisdiction in connection with such suit or proceedings and venue shall be appropriate for all purposes in such courts. 
 5.4
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

5.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 5.6 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earliest of (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during normal business hours of the recipient, and if not
sent during normal business hours, then on the recipient’s next business day, provided that in either case it is followed promptly by a confirming copy of the notice given via another authorized means for that recipient, (c) five (5)
business days after having been sent to a U.S. address by registered or certified mail, return receipt requested, postage prepaid, (d) in the case of delivery to a U.S. address, one (1) business day after deposit with a nationally
recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt, or (e) in the case of delivery to a non-U.S. address, three (3) business
days after deposit with an internationally recognized courier, freight prepaid, specifying next available business day delivery, with written verification of receipt; provided, however, that notice and other communications given or made to Roche
Finance Ltd shall only be provided using the methods set forth in clauses (a), (b) and (e) above. All communications to the Investors shall be sent to their respective addresses set forth on the signature page or Schedule A, or to such e-mail address or address as subsequently modified by written notice given in accordance with this Section 5.6. All communications to the Company shall be sent to: 

Ideaya Biosciences, Inc. 
 7000
Shoreline Court, Suite 350 
 South San Francisco, CA 94080 

Attn: Chief Executive Officer 

  
 20 

 with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park,
California 94025 
 Attn: Mark Roeder, Esq. 

Email: mark.roeder@lw.com 

Facsimile: (650) 463-2600 

5.7 Amendments and Waivers; Termination. This Agreement may be terminated, any term of this Agreement (other than Sections 3.1,
3.2, 3.3 and 3.9) may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the Holders of at least 65% of the Registrable Securities then-outstanding; provided, however, that no consent or approval of any Holder shall be required to add persons as parties to this Agreement as Investors pursuant to
Section 5.10 or to revise Schedule A to include such parties; and provided further, however, that neither this Agreement nor any term hereof may be amended, waived, or terminated in a manner that materially,
adversely and disproportionately affects any Investor in a manner different than all other Investors (disregarding for such purpose differences in the number of shares held by Investors) without the written consent of such Investor. The provisions
of Sections 3.1, 3.2, 3.3 and 3.9 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Major Investors
holding 65% of the Registrable Securities that are held by all of the Major Investors. The provisions of Section 3.10 relating to the Company’s (or its affiliates’) use of Celgene’s, Roche’s or
Novartis’ (or their respective affiliates’) names may be amended or waived only with the written consent of Celgene, Roche or Novartis, as the case may be, and for the avoidance of doubt, this sentence of this Section 5.7 shall not be
amended or waived with respect to Celgene, Roche or Novartis without such Investor’s written consent. To the extent that an amendment to Section 3.9 would impact an Investor with Observer Rights, such amendment shall
require the written consent of the impacted Investor with Observer Rights, as well as the written consent of the Company and the Holders of at least 65% of the Registrable Securities then-outstanding. Notwithstanding the foregoing, any right of any
party hereunder may be waived by the waiving party on such party’s own behalf, without the consent of any other party. Any amendment, waiver or termination effected in accordance with this Section 5.7 shall be binding
upon each Investor and the Company. 
 5.8 Severability. If any provision of this Agreement is held to be invalid, illegal or
unenforceable in any respect, such provision will be enforced to the maximum extent possible and such invalidity, illegality or unenforceability will not affect any other provision of this Agreement. In such event, the parties shall negotiate, in
good faith, a legal, valid and enforceable substitute provision which most nearly effects the intent of the parties in entering into this Agreement. 

5.9 Right to Invest. The Company on behalf of itself and its subsidiaries (a) acknowledges that certain of the Holders (the
“Investor Parties”) are in the business of making investments in, and have or may have investments in, other businesses similar to and that may compete with the businesses of the Company and its subsidiaries (“Competing
Businesses”) and (b) agrees that the Investor Parties shall have the unfettered right to make investments in or have relationships with other Competing Businesses independent of their investments in the Company. 

  
 21 

 5.10 Additional Parties. Persons who become “Purchasers” after the
effective date of this Agreement pursuant to and in accordance with the Purchase Agreement (each, an “Additional Party”), upon execution and delivery of counterpart signature pages to this Agreement, shall become parties hereto,
each such Additional Party thereby agreeing to be bound by and subject to the terms of this Agreement as an Investor hereunder. Each such Additional Party shall thereafter shall be deemed an Investor for all purposes under this Agreement. 

5.11 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to either party to this Agreement, upon
any breach or default of the other party to this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 5.12 Aggregation of Stock. All shares of Registrable Securities of the Company held or acquired by a stockholder and
its affiliated entities shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13 Electronic and Facsimile Signatures. Any signature page delivered electronically or by facsimile (including without limitation
transmission by .pdf) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto. Any party who delivers such a signature page agrees to later deliver an
original counterpart to the other party if so requested. 
 5.14 Entire Agreement. This Agreement (including all schedules and
exhibits attached hereto, if any) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof and hereby supersedes all other agreements of the parties to the extent such agreements relate
to the subject matter hereof. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded in its entirety by this Agreement, and shall be of no further force or effect. 

5.15 Advice of Counsel. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY
TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF. 

(Signature pages follow) 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	COMPANY:
	
	IDEAYA BIOSCIENCES, INC.

 
			
		
	By: 	 	/s/ Yujiro Hata

 
			
	Name: Yujiro Hata
	Title: Chief Executive Officer and President

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	GV 2017, L.P.
	
	By: GV 2017 GP, L.P., its General Partner
	By: GV 2017 GP, L.L.C., its General Partner
		
	By: 	 	/s/ Daphne M. Chang
	Name: Daphne M. Chang
	Title: Authorized Signatory

 Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	5AM VENTURES IV, L.P.
	
	By: 5AM Partners IV, LLC, its General Partner

 
			
		
	By: 	 	/s/ John D. Diekman

 
			
	Name:	 	John D. Diekman
	Title:	 	Managing Member

  

			
	5AM CO-INVESTORS IV, L.P.
	
	By: 5AM Partners IV, LLC, its General Partner

 
			
		
	By: 	 	/s/ John D. Diekman

 
			
	Name:	 	John D. Diekman
	Title:	 	Managing Member

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	CANAAN X LP
	
	 By: Canaan Partners X LLC,
 its
general Partner

		
	By:	 	 /s/ Timothy M. Shannon

		 	Manager

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	CELGENE CORPORATION

 
			
		
	By: 	 	/s/ Jonathan Biller

 
			
	Name:	 	Jonathan Biller
	Title:	 	SVP Tax & Treasury
	Address:	 	 86 Morris Avenue
 Summit, NJ
07901

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:

  

			
	 ALEXANDRIA VENTURE INVESTMENTS, LLC,

a Delaware limited liability company

		
	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, INC.,
 a
Maryland corporation, managing member

		
	By:	 	 /s/ Aaron Jacobson

		 	Name: Aaron Jacobson
		 	Title: VP - Corporate Counsel
		
		 	Address: 385 E. Colorado Blvd., Suite 299                Pasadena, CA 91101

 [Signature page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
	INVESTORS:

  

					
	VP COMPANY INVESTMENTS 2008, LLC
		
	By: 	 	 /s/ ALAN C. MENDELSON

					
	Name:	 	ALAN C. MENDELSON

 
					
	Title:	 	MEMBER OF MANAGEMENT COMMITTEE

  

					
	VP COMPANY INVESTMENTS 2016, LLC
		
	By: 	 	 /s/ ALAN C.
MENDELSON

 
					
	Name:	 	ALAN C. MENDELSON

 
					
	Title:	 	MEMBER OF MANAGEMENT COMMITTEE

 [Signature page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

	
	INVESTOR:
	
	MARK V. ROEDER
	
	 /s/ MARK V. ROEDER

	Signature

 [Signature page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:

  

			
	THE ALAN C. AND AGNÉS B. MENDELSON FAMILY TRUST
		
	By:	 	 /s/ ALAN C. MENDELSON

			
	Name:	 	ALAN C. MENDELSON

 
			
	Title:	 	TRUSTEE

 
			
	Address:	 	[PRIVATE ADDRESS]

 [Signature page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:

  

			
	WUXI HEALTHCARE VENTURES II, L.P.
		
	By:	 	WUXI HEALTHCARE MANAGEMENT, LLC, its General Partner
		
	By:	 	/s/ Wei Li

 
			
	Its:	 	Director

 [Signature page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	6 Dimensions Capital, L.P.
	
	By: 6 Dimensions Capital GP, LLC, its General Partner
		
	By:	 	/s/ CHRISTINA CHUNG
	Name: 	 	CHRISTINA CHUNG
	Title:	 	CFO
	
	6 Dimensions Affiliates Fund, L.P.
	
	By: 6 Dimensions Capital GP, LLC, its General Partner
		
	By:	 	/s/ CHRISTINA CHUNG
	Name: 	 	CHRISTINA CHUNG
	Title:	 	CFO

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	BIOTECHNOLOGY VALUE FUND, L.P.
		
	By:	 	/s/ Mark Lampert

 
			
	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF
	Partners L.P., itself GP of Biotechnology Value Fund, L.P.
	
	Address:
	 1 Sansome Street #30
 San Francisco,
CA 94104

  

			
	BIOTECHNOLOGY VALUE FUND II, L.P.
		
	By:	 	/s/ Mark Lampert

 
			
	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF
	Partners L.P., itself GP of Biotechnology Value Fund II, L.P.
	
	Address:
	 1 Sansome Street #30
 San Francisco,
CA 94104

  

			
	BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.
		
	By:	 	/s/ Mark Lampert

 
			
	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF
	Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Trading Fund OS, L.P.
	
	Address:
	PO Box 309 Ugland House, Grand Cayman, KY1-1104, Cayman Islands

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	INVESTMENT 10, LLC
		
	By:	 	/s/ Mark Lampert

 
			
	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF
	Partners L.P., itself attorney-in-fact for Investment 10, LLC
	
	Address:
	 900 N Michigan Ave Suite 1100

Chicago, IL 60611

  

			
	MSI BVF SPV, L.L.C.
	
	c/o Magnitude Capital
		
	By:	 	/s/ Mark Lampert

 
			
	Name: Mark Lampert
	Title: President BVF Inc., itself General Partner
	 of BVF Partners L.P., itself attorney-in-fact
for
 MSI BVF SPV, L.L.C.

	
	Address:
	 200 Park Avenue, 56th Floor

New York, NY 10166

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
		
	By:	 	/s/ James H Mannix

 
			
	Name:	 	James H Mannix

 
			
	Title:	 	C.O.O.

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	NEXTECH IV GP S.À.R.L. ON BEHALF OF
	NEXTECH IV ONCOLOGY S.C.S. SICAV-SIF
	
	By its Manager of Nextech IV GP S.à.r.l

 
					
			
	By:	 	/s/ Marc Kriegsmann	 	/s/ Christoph Kraiker
	Name: 	 	Marc Kriegsmann	 	Christoph Kraiker
	Title:	 	Manager	 	Manager

  

					
	NEXTECH V GP S.À.R.L. ON BEHALF OF
	NEXTECH V ONCOLOGY S.C.S. SI CAV-SIF
	
	By its Managers
			
	By:	 	/s/ James Vella-Bamber	 	/s/ James Pledger
	Name:	 	James Vella-Bamber	 	James Pledger
	Title:	 	Manager	 	Manager

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	Boxer Capital, LLC
		
	By:	 	 /s/ Aaron Davis

 
			
	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer
	
	Address:
	 11682 E1 Camino Real, Suite 320
 San
Diego, CA 92130

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	ROCHE FINANCE LTD
		
	By:	 	 /s/ Carole Nuechterlein

			
	Name:	 	Carole Nuechterlein
	Title:	 	authorized signatory

  

			
	By:	 	 /s/ Andreas Knierzinger

			
	Name:	 	Andreas Knierzinger
	Title:	 	authorized signatory

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
	INVESTOR:
	
	DRIEHAUS EVENT DRIVEN FUND, A SERIES OF DRIEHAUS MUTUAL FUNDS
		
	By:	 	 /s/ Janet McWilliams

			
	Name:	 	Janet McWilliams
	Title:	 	Chief Legal Officer

 [Signature Page to Ideaya Biosciences, Inc. Amended and Restated Investors’ Rights Agreement]

 SCHEDULE A 

Schedule of Investors 
 5AM Ventures IV,
L.P. 
 501 Second Street, Suite 350 
 San Francisco, CA 94107

 Attn: Paul Stone 
 Email: [PRIVATE EMAIL] 

5AM Co-Investors IV, L.P. 

501 Second Street, Suite 350 
 San Francisco, CA 94107 

Attn: Paul Stone 
 Email: [PRIVATE EMAIL] 

Canaan X L.P. 
 285 Riverside Avenue 

Suite 250 
 Westport, CT 06880 

Attn: Dr. Tim Shannon 
 [PRIVATE EMAIL] 

Novartis Institutes for BioMedical Research, Inc. 
 250
Massachusetts Avenue 
 Cambridge, MA 02139 
 Attn: General
Counsel 
 Celgene Corporation 
 86 Morris Avenue 

Summit, NJ 07901 
 ATTN: Head of BD & AM 

Copy to: VP, Legal BD 
 Phone: 908-673-9000 
 Fax: 908-897-6760

 Alexandria Venture Investments, LLC 
 385 E. Colorado Blvd.,
Suite 299 
 Pasadena, CA 91101 
 Attn: Krystal Garcia 

Email: [PRIVATE EMAIL] 
 VP Company Investments 2008, LLC 

c/o Latham & Watkins LLP 
 Attn: Alfred Harutunian 

555 West Fifth Street – Suite 800 
 Los Angeles, CA
90013-1021 
 Fax: (213) 891-1200 

Email: [PRIVATE EMAIL] 
 Mark V. Roeder 

Latham & Watkins LLP 
 140 Scott Drive 

Menlo Park, CA 94025 

 The Alan C. and Agnés B. Mendelson Family Trust 

[PRIVATE ADDRESS] 
 WuXi Healthcare Ventures II, L.P. 

222 Third Street, Suite 1100 
 Cambridge, MA 02142 

Driehaus Event Driven Fund 
 25 East Erie Street 

Chicago, IL 60611 
 Attn: Janet McWilliams 

Perceptive Life Sciences Master Fund LTD 
 51 Astor Place 10th Floor 
 New York, NY 10003 

Nextech IV GP S.à.r.l. on behalf of 
 Nextech IV Oncology
S.C.S. SICAV-SIF 
 1c, rue Gabriel Lippmann 

L-5365 Munsbach 
 Attn:
The board of manager of Nextech IV GP S.à r.l. 
 [PRIVATE EMAIL] 

with a copy to: 
 Cooley LLP 

11951 Freedom Drive 
 Reston, VA 20190 

Attention: Christian Plaza 
 [PRIVATE EMAIL] 

Nextech V GP S.à r.l. on behalf of Nextech V Oncology 

S.C.S., SICAV-SIF 
 8, Rue Lou Hemmer 

L-1748 Louxembourg-Findel 
 Grand-Duchy of Luxembourg 

Attn: The Managers of Nextech V GP S.à r.l. 
 [PRIVATE EMAIL]

 with a copy to: 
 Cooley LLP 

11951 Freedom Drive 
 Reston, VA 20190 

Attention: Christian Plaza 
 [PRIVATE EMAIL] 

 6 Dimensions Capital, L.P. 

Unit 6706, The Center, 99 Queen’s Road Central, 
 Central,
Hong Kong 
 6 Dimensions Affiliates Fund, L.P 
 Unit 6706, The
Center, 99 Queen’s Road Central, 
 Central, Hong Kong 

Roche Finance Ltd 
 Grenzacherstrasse 122 

4070 Basel, Switzerland 
 Fax: + 41 61 687 0644 

Attn: Roche Venture Fund, Carole Nuechterlein 
 With a
simultaneous copy (which shall not constitute notice) to: 
 Hoffmann-La Roche Inc. 

Overlook at Great Notch 
 150 Clove Road 

8th Floor – Suite 8 
 Little Falls, NJ 07424 

Attn: General Counsel 
 Boxer Capital, LLC 

11682 El Camino Real 
 Suite 320 

San Diego, CA 92130 
 Attn: Christopher D. Fuglesang 

[PRIVATE EMAIL] 
 Biotechnology Value Fund, L.P. 

1 Sansome Street #30 
 San Francisco, CA 94104 

[PRIVATE EMAIL] 
 Biotechnology Value Fund II, LP 

1 Sansome Street #30 
 San Francisco, CA 94104 

[PRIVATE EMAIL] 
 Biotechnology Value Trading Fund OS, L.P. 

PO Box 309 Ugland House 
 Grand Cayman, KY1-1104 
 Cayman Islands 

[PRIVATE EMAIL] 
 Investment 10, LLC 

90 N Michigan Ave Suite 1100 
 Chicago, IL 60611 

[PRIVATE EMAIL] 

 MSI BVF SPV, L.L.C. 

200 Park Avenue, 56th Floor 

New York, NY 10166 

[PRIVATE EMAIL] 

GV 2017, L.P. 

Attn: GV Legal Department 

1600 Amphitheatre Parkway 

Mountain View, CA 94043 

[PRIVATE EMAIL]EX-10.4(a)

 Exhibit 10.4(a) 

IDEAYA BIOSCIENCES, INC. 

2015 EQUITY INCENTIVE PLAN 

1. Purpose. 
 The
purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing
such persons with equity ownership opportunities and thereby better aligning the interests of such persons with those of the Company’s stockholders. Capitalized terms used in the Plan are defined in Section 11 below. 

2. Eligibility. 

Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. 

3. Administration and Delegation. 

(a) Administration. The Plan will be administered by the Administrator. The Administrator shall have authority to determine
which Service Providers will receive Awards, to grant Awards and to set all terms and conditions of Awards (including, but not limited to, vesting, exercise and forfeiture provisions). In addition, the Administrator shall have the authority to take
all actions and make all determinations contemplated by the Plan and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Administrator may correct any defect or
ambiguity, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem necessary or appropriate to carry the Plan and any Awards into effect, as determined by the Administrator. The
Administrator shall make all determinations under the Plan in the Administrator’s sole discretion and all such determinations shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. 

(b) Appointment of Committees. To the extent permitted by Applicable Laws, the Board may delegate
any or all of its powers under the Plan to one or more Committees. The Board may abolish any Committee at any time and re-vest in itself any previously delegated authority. 

4. Stock Available for Awards. 

(a) Number of Shares. Subject to adjustment under Section 8 hereof, Awards may be made under
the Plan covering up to 1,200,000 shares of Common Stock. If any Award expires or lapses or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common
Stock subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company,
the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the
applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall be added to
the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares of
Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market or treasury shares. 

 (b) Substitute Awards. In connection with a merger or consolidation of
an entity with the Company or the acquisition by the Company of property or stock of an entity, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by
such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Administrator deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count
against the overall share limit set forth in Section 4(a) hereof, except as may be required by reason of Section 422 of the Code. 

5. Stock Options. 

(a) General. The Administrator may grant Options to any Service Provider, subject to the limitations on Incentive Stock
Options described below. The Administrator shall determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including
conditions relating to Applicable Laws, as it considers necessary or advisable. 
 (b) Incentive Stock
Options. The Administrator may grant Options intended to qualify as Incentive Stock Options only to employees of the Company, any of the Company’s present or future “parent corporations” or “subsidiary
corporations” as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. All Options intended to qualify as Incentive Stock
Options shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code. Neither the Company nor the Administrator shall have any liability to a Participant, or any other party, (i) if an Option (or
any part thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as an Incentive Stock Option or (ii) for any action or omission by the Administrator that causes an Option not to qualify as an Incentive Stock Option,
including without limitation, the conversion of an Incentive Stock Option to a Non-Qualified Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements
under the Code applicable to an Incentive Stock Option. Any Option that is intended to qualify as an Incentive Stock Option, but fails to so qualify for any reason, including without limitation, the portion of any Option becoming exercisable in
excess of the $100,000 limitation described in Treasury Regulation Section 1.422-4, shall be treated as a Non-Qualified Stock Option for all purposes. 

(c) Exercise Price. The Administrator shall establish the exercise price of each Option and specify the exercise
price in the applicable Award Agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the
Option, owns (or is treated as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a “parent corporation” or “subsidiary corporation” thereof
within the meaning of Sections 424(e) or 424(f) of the Code, respectively), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted. 

(d) Duration of Options. Each Option shall be exercisable at such times and subject to such
terms and conditions as the Administrator may specify in the applicable Award Agreement, provided that the term of any Option shall not exceed ten years. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of
the Option, owns (or is treated as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a “parent corporation” or “subsidiary corporation”
thereof within the meaning of Sections 424(e) or 424(f) of the Code, respectively), the term of the Option shall not exceed five years. 

  
 2 

 (e) Exercise of Option; Notification of Disposition. Options may be exercised by
delivery to the Company of a written notice of exercise, in a form approved by the Administrator (which may be an electronic form), signed by the person authorized to exercise the Option, together with payment in full (i) as specified in
Section 5(f) hereof for the number of shares for which the Option is exercised and (ii) as specified in Section 9(e) hereof for any applicable withholding taxes. Unless otherwise determined by the Administrator, an Option may not be
exercised for a fraction of a share of Common Stock. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired from
the Option if such disposition or transfer is made (i) within two years from the grant date with respect to such Option or (ii) within one year after the transfer of such shares to the Participant (other than any such disposition made in
connection with a Change in Control). Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such
disposition or other transfer. 
 (f) Payment Upon Exercise. Common Stock purchased upon the
exercise of an Option granted under the Plan shall be paid for in cash or by check, payable to the order of the Company, or, to the extent permitted by the Administrator, by: 

(i) (A) delivery of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to
the Company sufficient funds to pay the exercise price and any required tax withholding, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver
promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 
 (ii)
delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (A) such method of payment is then permitted under Applicable Laws, (B) such Common Stock,
if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Company at any time, and (C) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled
vesting or other similar requirements; 
 (iii) surrendering shares of Common Stock then issuable upon exercise of the Option
valued at their Fair Market Value on the date of exercise; 
 (iv) delivery of a promissory note of the Participant to the
Company on terms determined by the Administrator; 
 (v) delivery of property of any other kind which constitutes good and
valuable consideration as determined by the Administrator; or 
 (vi) any combination of the above permitted forms of payment
(including cash or check). 
 (g) Early Exercise of Options. The Administrator may provide
in the terms of an Award Agreement that the Service Provider may exercise an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock with respect to any unvested portion of the Option so
exercised. Shares of Restricted Stock acquired upon the exercise of any unvested portion of an Option shall be subject to such terms and conditions as the Administrator shall determine. 

  
 3 

 6. Restricted Stock;
Restricted Stock Units. 
 (a) General. The Administrator may
grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or
to require forfeiture of such shares if issued at no cost) in the event that conditions specified by the Administrator in the applicable Award Agreement are not satisfied prior to the end of the applicable restriction period or periods established
by the Administrator for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during applicable restriction period or periods, as set forth in an
applicable Award Agreement. 
 (b) Terms and Conditions for All
Restricted Stock and Restricted Stock Unit Awards. The Administrator shall determine and set forth in the applicable Award Agreement the terms and
conditions applicable to each Restricted Stock and Restricted Stock Unit Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, in each case, if any. 

(c) Additional Provisions Relating to Restricted Stock. 

(i) Dividends. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with
respect to such shares to the extent such dividends have a record date that is on or after the date on which the Participant to whom such Restricted Shares are granted becomes the record holder of such Restricted Shares, unless otherwise provided by
the Administrator in the applicable Award Agreement. In addition, unless otherwise provided by the Administrator, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock of property
other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be
made as provided in the applicable Award Agreement, but in no event later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the later of
(A) the date the dividends are paid to stockholders of that class of stock, and (B) the date the dividends are no longer subject to forfeiture. 

(ii) Stock Certificates. The Company may require that any stock certificates issued in respect of shares
of Restricted Stock be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). 

(d) Additional Provisions Relating to Restricted Stock
Units. 
 (i) Settlement. Upon the vesting of a Restricted Stock Unit, the Participant shall be entitled to
receive from the Company one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date, as the Administrator shall determine and as provided in the applicable
Award Agreement. The Administrator may provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on a mandatory basis or at
the election of the Participant, in a manner that complies with Section 409A. 
 (ii) Voting
Rights. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof. 

  
 4 

 (iii) Dividend Equivalents. To the extent provided by
the Administrator, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or
shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are paid, as determined by the Administrator, subject, in each case, to
such terms and conditions as the Administrator shall establish and set forth in the applicable Award Agreement. 
 7.
Other Stock-Based Awards. 
 Other Stock-Based Awards may be
granted hereunder to Participants, including, without limitation, Awards entitling Participants to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the
settlement of other Awards granted under the Plan, as stand-alone payments and/or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock, cash or other
property, as the Administrator shall determine. Subject to the provisions of the Plan, the Administrator shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting
conditions and other terms and conditions applicable thereto, which shall be set forth in the applicable Award Agreement. 
 8.
Adjustments for Changes in Common Stock and Certain Other Events. 

(a) In the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Common Stock, other
securities, or other property), reorganization, merger, consolidation, combination, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or
sale or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the
Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under
the Plan or with respect to any Award, then the Administrator may, in such manner as it may deem equitable, adjust any or all of: 

(i) the number and kind of shares of Common Stock (or other securities or property) with respect to which Awards may be granted
or awarded (including, but not limited to, adjustments of the limitations in Section 4 hereof on the maximum number and kind of shares which may be issued); 

(ii) the number and kind of shares of Common Stock (or other securities or property) subject to outstanding Awards; 

(iii) the grant or exercise price with respect to any Award; and 

(iv) the terms and conditions of any Awards (including, without limitation, any applicable financial or other performance
“targets” specified in an Award Agreement). 
 (b) In the event of any transaction or event described in Section 8(a) hereof
(including without limitation any Change in Control) or any unusual or nonrecurring transaction or event affecting the Company or the financial statements of the Company, or any change in any Applicable Laws or accounting principles, the
Administrator, on such terms and conditions as it deems appropriate, either 

  
 5 

 
by the terms of the Award or by action taken prior to the occurrence of such transaction or event and either automatically or upon the Participant’s request, is hereby authorized to take any
one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the
Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles: 

(i) To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value
equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant’s rights under the vested portion of such Award, as applicable; provided that, if the amount
that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant’s rights, in any case, is equal to or less than zero, then the vested portion of such Award may be terminated
without payment; 
 (ii) To provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares
covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; 
 (iii) To provide
that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with
appropriate adjustments as to the number and kind of shares and applicable exercise or purchase price, in all cases, as determined by the Administrator; 

(iv) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to
outstanding Awards, and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards which may be granted in the future; 

(v) To replace such Award with other rights or property selected by the Administrator; and/or 

(vi) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. 

(c) Notwithstanding the provisions of Section 8(b) above, if a Change in Control occurs and a Participant’s Awards are not
continued, converted, assumed, or replaced with a substantially similar award by (i) the Company, or (ii) a successor entity or its parent or subsidiary (an “Assumption”), and provided that the Participant has not
had a Termination of Service, then immediately prior to the Change in Control such Awards shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in
which case, such Awards shall be canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (A) which may be on such terms and
conditions as apply generally to holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, earn-out or other deferred consideration provisions) or such other
terms and conditions as the Administrator may provide, and (B) determined by reference to the number of shares subject to such Awards and net of any applicable exercise price; provided that to the extent that any Awards constitute
“nonqualified deferred compensation” that may not be paid upon the Change in Control under Section 409A without the imposition of taxes thereon under Section 409A, the timing of such payments shall be governed by the applicable
Award Agreement 

  
 6 

 
(subject to any deferred consideration provisions applicable under the Change in Control documents); and provided, further, that if the amount to which a Participant would be entitled upon the
settlement or exercise of such Award at the time of the Change in Control is equal to or less than zero, then such Award may be terminated without payment. The Administrator shall determine whether an Assumption of an Award has occurred in
connection with a Change in Control. 
 (d) In connection with the occurrence of any Equity Restructuring, and notwithstanding anything to
the contrary in this Section 8, the Administrator will equitably adjust each outstanding Award, which adjustments may include adjustments to the number and type of securities subject to each outstanding Award and/or the exercise price or grant
price thereof, if applicable, the grant of new Awards to Participants, and/or the making of a cash payment to Participants, as the Administrator deems appropriate to reflect such Equity Restructuring. The adjustments provided under this
Section 8(d) shall be nondiscretionary and shall be final and binding on the affected Participant and the Company; provided that whether an adjustment is equitable shall be determined by the Administrator. 

(e) In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution
(other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock, including any Equity Restructuring, for reasons of administrative convenience the
Administrator may refuse to permit the exercise of any Award during a period of up to thirty days prior to the consummation of any such transaction. 

(f) Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no Participant shall have any rights
by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the
Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any
class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Common Stock subject to an Award or the grant or exercise price of any Award. The existence of the Plan, any Award Agreements and the
Awards granted hereunder shall not affect or restrict in any way the right or power of the Company to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or its business,
(ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including without limitation, securities with rights superior to those of the Common Stock or
which are convertible into or exchangeable for Common Stock. The Administrator may treat Participants and Awards (or portions thereof) differently under this Section 8. 

9. General Provisions Applicable to
Awards. 
 (a) Transferability. Except as the Administrator may otherwise determine or provide in
an Award Agreement or otherwise, in any case in accordance with Applicable Laws, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law,
except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized
transferees. 
 (b) Documentation. Each Award shall be evidenced in an Award Agreement, which may be in such form (written,
electronic or otherwise) as the Administrator shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. 

  
 7 

 (c) Discretion. Except as otherwise provided by the Plan, each Award may be
made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. 

(d) Termination of Status. The Administrator shall determine the effect on an Award of the
disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant’s Service Provider status and the extent to which, and the period during which, the Participant, the Participant’s legal
representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable. 
 (e)
Withholding. Each Participant shall pay to the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with Awards to such Participant no later than the date
of the event creating the tax liability. Except as the Administrator may otherwise determine, all such payments shall be made in cash or by certified check. Notwithstanding the foregoing, to the extent permitted by the Administrator, Participants
may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value. The Company may, to the extent permitted by
Applicable Laws, deduct any such tax obligations from any payment of any kind otherwise due to a Participant. 
 (f) Amendment
of Award. The Administrator may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or
settlement, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant’s consent to such action shall be required unless (i) the Administrator determines that the
action, taking into account any related action, would not materially and adversely affect the Participant, or (ii) the change is permitted under Section 8 and 10(f) hereof. 

(g) Conditions on Delivery of Stock. The Company will not be obligated
to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in
the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and
regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy the requirements of any Applicable Laws. The inability of the
Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the Administrator to be necessary to the lawful issuance and sale of any securities hereunder, shall relieve the Company of any liability in
respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained. 
 (h)
Acceleration. The Administrator may at any time provide that any Award shall become immediately vested and/or exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part,
as the case may be. 
 10. Miscellaneous. 

(a) No Right To Employment or Other Status.
No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves
the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an applicable Award Agreement. 

  
 8 

 (b) No Rights As Stockholder;
Certificates. Subject to the provisions of the applicable Award Agreement, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to
an Award until becoming the record holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by any Applicable Laws, the Company shall not be required to deliver to any
Participant certificates evidencing shares of Common Stock issued in connection with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator).
The Company may place legends on any stock certificates issued under the Plan deemed necessary or appropriate by the Administrator in order to comply with Applicable Laws. 

(c) Effective Date and Term of Plan. The Plan shall become
effective on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the completion of ten years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan
was approved by the Company’s stockholders, but Awards previously granted may extend beyond that date in accordance with the terms of the Plan. 

(d) Amendment of Plan. The Administrator may amend, suspend or terminate the Plan or any portion
thereof at any time; provided that no amendment of the Plan shall materially and adversely affect any Award outstanding at the time of such amendment without the consent of the affected Participant. Awards outstanding under the Plan at the time of
any suspension or termination of the Plan shall continue to be governed in accordance with the terms of the Plan and the applicable Award Agreement, as in effect prior to such suspension or termination. The Board shall obtain stockholder approval of
any Plan amendment to the extent necessary to comply with Applicable Laws. 
 (e) Provisions for
Foreign Participants. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in
laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. 

(f) Section 409A. 

(i) General. The Company intends that all Awards be structured in compliance with, or to satisfy an exemption from,
Section 409A, such that no adverse tax consequences, interest, or penalties under Section 409A apply in connection with any Awards. Notwithstanding anything herein or in any Award Agreement to the contrary, the Administrator may, without a
Participant’s prior consent, amend this Plan and/or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and actions with retroactive effect) as are necessary or appropriate to preserve
the intended tax treatment of Awards under the Plan, including without limitation, any such actions intended to (A) exempt this Plan and/or any Award from the application of Section 409A, and/or (B) comply with the requirements of
Section 409A, including without limitation any such regulations, guidance, compliance programs and other interpretative authority that may be issued after the date of grant of any Award. The Company makes no representations or warranties as to
the tax treatment of any Award under Section 409A or otherwise. The Company shall have no obligation under this Section 10(f) or otherwise to take any action (whether or not described herein) to avoid the imposition of taxes, penalties or
interest under Section 409A with respect to any Award and shall have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute
non-compliant, “nonqualified deferred compensation” subject to the imposition of taxes, penalties and/or interest under Section 409A. 

  
 9 

 (ii) Separation from Service. With
respect to any Award that constitutes “nonqualified deferred compensation” under Section 409A, any payment or settlement of such Award that is to be made upon a termination of a Participant’s Service Provider relationship shall,
to the extent necessary to avoid the imposition of taxes under Section 409A, be made only upon the Participant’s “separation from service” (within the meaning of Section 409A), whether such “separation from
service” occurs upon or subsequent to the termination of the Participant’s Service Provider relationship. For purposes of any such provision of this Plan or any Award Agreement relating to any such payments or benefits, references to a
“termination,” “termination of employment” or like terms shall mean “separation from service.” 

(iii) Payments to Specified Employees. Notwithstanding any contrary provision
in the Plan or any Award Agreement, any payment(s) of “nonqualified deferred compensation” that are otherwise required to be made under an Award to a “specified employee” (as defined under Section 409A and determined by the
Administrator) as a result of his or her “separation from service” shall, to the extent necessary to avoid the imposition of taxes under Code Section 409A(a)(2)(B)(i), be delayed until the expiration of the six-month period immediately following such “separation from service” (or, if earlier, until the date of death of the specified employee) and shall instead be paid (in a manner set forth in the Award
agreement) on the day that immediately follows the end of such six-month period or as soon as administratively practicable thereafter (without interest). Any payments of “nonqualified deferred
compensation” under such Award that are, by their terms, payable more than six months following the Participant’s “separation from service” shall be paid at the time or times such payments are otherwise scheduled to be made. 

(g) Limitations on Liability. Notwithstanding any other provisions of the Plan, no individual acting as a
director, officer, other employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award,
nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as an Administrator, director, officer, other employee or agent of the Company. The Company
will indemnify and hold harmless each director, officer, other employee and agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be granted or delegated, against any cost or
expense (including attorneys’ fees) or liability (including any sum paid in settlement of a claim with the Administrator’s approval) arising out of any act or omission to act concerning this Plan unless arising out of such person’s
own fraud or bad faith. 
 (h) Lock-Up Period. The Company may, at the request
of any representative of the underwriters or otherwise, in connection with any registration of the offering of any securities of the Company under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise
transferring any shares of Common Stock or other securities of the Company during a period of up to one hundred eighty days following the effective date of a registration statement of the Company filed under the Securities Act. 

(i) Right of First Refusal. 

(i) Before any shares of Common Stock held by a Participant or any permitted transferee (each, a
“Holder”) may be sold, pledged, assigned, hypothecated, transferred, or otherwise disposed of (each, a “Transfer”), the Company or its assignee(s) shall have a right of first refusal to purchase the
shares of Common Stock proposed to be Transferred 

  
 10 

 
on the terms and conditions set forth in this Section 10(i) (the “Right of First Refusal”). In the event that the Company’s charter, bylaws and/or a
stockholders’ agreement applicable to the shares of Common Stock contain a right of first refusal with respect to the shares of Common Stock, such right of first refusal shall apply to the shares of Common Stock to the extent such provisions
are more restrictive than the Right of First Refusal set forth in this Section 10(i) and the Right of First Refusal set forth in this Section 10(i) shall not in any way restrict the operation of the Company’s charter, bylaws or the
operation of any applicable stockholders’ agreement. 
 (ii) In the event any Holder desires to Transfer any shares of
Common Stock, the Holder shall deliver to the Company a written notice (the “Notice”) stating: (A) the Holder’s bona fide intention to sell or otherwise Transfer such shares of Common Stock; (B) the name of
each proposed purchaser or other transferee (“Proposed Transferee”); (C) the number of shares of Common Stock to be Transferred to each Proposed Transferee; and (D) the price for which the
Holder proposes to Transfer the shares of Common Stock (the “Offered Price”), and the Holder shall offer such shares of Common Stock at the Offered Price to the Company or its assignee(s). 

(iii) Within twenty-five days after receipt of the Notice, the Company and/or its assignee(s) may elect in writing to purchase
all, but not less than all, of the shares of Common Stock proposed to be Transferred to any one or more of the Proposed Transferees by delivery of a written exercise notice to the Holder (a “Company
Notice”). The purchase price (“Purchase Price”) for the shares of Common Stock repurchased under this Section 10(i) shall be the Offered Price. 

(iv) Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check or wire
transfer), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof, within five days after delivery of the
Company Notice or in the manner and at the times mutually agreed to by the Company and the Holder. Should the Offered Price specified in the Notice be payable in property other than cash, the Company or its assignee shall have the right to pay the
purchase price in the form of cash equal in amount to the value of such property, as determined by the Administrator. 
 (v)
If all or a portion of the shares of Common Stock proposed in the Notice to be Transferred are not purchased by the Company and/or its assignee(s) as provided in this Section 10(i), then the Holder may sell or otherwise Transfer such shares of
Common Stock to that Proposed Transferee at the Offered Price or at a higher price; provided that such sale or other Transfer is consummated within sixty days after the date of the Notice; and provided, further, that any such sale or other Transfer
is effected in accordance with any Applicable Laws and the Proposed Transferee agrees in writing that the provisions of this Plan and the applicable Award Agreement and any other applicable agreements governing the shares of Common Stock to be
Transferred shall continue to apply to the shares of Common Stock in the hands of such Proposed Transferee. If the shares of Common Stock described in the Notice are not Transferred to the Proposed Transferee within such sixty-day period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal, as provided herein, before any shares of Common Stock held by the
Holder may be sold or otherwise Transferred. 
 (vi) Anything to the contrary contained in this Section 10(i)
notwithstanding and to the extent permitted by the Administrator, the Transfer of any or all of the shares of Common Stock during a Participant’s lifetime or upon a Participant’s death by will or intestacy to the Participant’s
Immediate Family or a trust for the benefit of the Participant’s Immediate Family shall be exempt from the Right of First Refusal. As used herein, “Immediate Family”

  
 11 

 
shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister or stepchild (whether or not adopted). In such case, the transferee or other recipient shall receive and hold
the shares of Common Stock so Transferred subject to the provisions of this Plan (including the Right of First Refusal), the applicable Award Agreement and any other applicable agreements governing the shares of Common Stock to be Transferred, and
there shall be no further Transfer of such shares of Common Stock except in accordance with the terms of this Section 10(i) (or otherwise as expressly provided under the Plan). 

(vii) The Right of First Refusal shall terminate as to all shares of Common Stock if the Company becomes a Publicly Listed
Company upon such occurrence. 
 (j) Data Privacy. As a condition of receipt of any Award, each Participant explicitly
and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its subsidiaries and affiliates for the exclusive purpose of
implementing, administering and managing the Participant’s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but not limited to, the
Participant’s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and
affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the “Data”). The Company and its subsidiaries and affiliates may transfer the Data amongst
themselves as necessary for the purpose of implementation, administration and management of a Participant’s participation in the Plan, and the Company and its subsidiaries and affiliates may each further transfer the Data to any third parties
assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant’s country, or elsewhere, and the Participant’s country may have different data privacy laws and
protections than the recipients’ country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing,
administering and managing the Participant’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares
of Common Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant’s participation in the Plan. A Participant may, at any time, view the Data held by the Company
with respect to such Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the Participant or refuse or withdraw the
consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel Participant’s ability to participate in the Plan and, in the Administrator’s discretion, the
Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact their
local human resources representative. 
 (k) Severability. In the event any portion of the Plan or any action taken pursuant thereto
shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal or invalid provisions had not been included, and the
illegal or invalid action shall be null and void. 
 (l) Governing Documents. In the event of any contradiction between
the Plan and any Award Agreement or any other written agreement between a Participant and the Company or any Subsidiary of the Company that has been approved by the Administrator, the terms of the Plan shall govern, unless it is expressly specified
in such Award Agreement or other written document that a specific provision of the Plan shall not apply. 

  
 12 

 (m) Submission to Jurisdiction; Waiver of Jury Trial. By accepting an Award, each
Participant irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of California and of the United States of America, in each case located in the State of California, for any action arising out of
or relating to the Plan (and agrees not to commence any litigation relating thereto except in such courts), and further agrees that service of any process, summons, notice or document by U.S. registered mail to the address contained in the records
of the Company shall be effective service of process for any litigation brought against it in any such court. By accepting an Award, each Participant irrevocably and unconditionally waives any objection to the laying of venue of any litigation
arising out of Plan or Award hereunder in the courts of the State of California or the United States of America, in each case located in the State of California, and further irrevocably and unconditionally waives and agrees not to plead or claim in
any such court that any such litigation brought in any such court has been brought in an inconvenient forum. By accepting an Award, each Participant irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any and
all rights to trial by jury in connection with any litigation arising out of or relating to the Plan or any Award hereunder. 
 (n)
Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of California, disregarding choice-of-law principles of the law of any state that would require the application of the laws of a jurisdiction other than such state. 

(o) Restrictions on Shares; Claw-back Provisions. Shares of Common Stock
acquired in respect of Awards shall be subject to such terms and conditions as the Administrator shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the Company to repurchase
shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Administrator, be contained in the applicable Award Agreement or in an
exercise notice, stockholders’ agreement or in such other agreement as the Administrator shall determine, in each case in a form determined by the Administrator. The issuance of such shares of Common Stock shall be conditioned on the
Participant’s consent to such terms and conditions and the Participant’s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant
upon any receipt or exercise of any Award or upon the receipt or resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any
claw-back policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such claw-back policy and/or in the applicable
Award Agreement. 
 (p) Titles and Headings. The titles and headings of the Sections in the Plan are for
convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. 

(q) Conformity to Securities Laws. Participant acknowledges that the Plan is intended to
conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations.
Notwithstanding anything herein to the contrary, the Plan and all Awards granted hereunder shall be administered only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by Applicable Laws, the Plan and all
Award Agreements shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 

  
 13 

 11. Definitions. As used in the Plan, the following words and
phrases shall have the following meanings: 
 (a) “Administrator” means the Board or a Committee to the extent that
the Board’s powers or authority under the Plan have been delegated to such Committee. 
 (b) “Applicable
Laws” means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock
exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted or issued under the Plan. 

(c) “Award” means, individually or collectively, a grant under the Plan of Options, Restricted Stock,
Restricted Stock Units or Other Stock-Based Awards. 
 (d) “Award Agreement”
means a written agreement evidencing an Award, which agreements may be in electronic medium and shall contain such terms and conditions with respect to an Award as the Administrator shall determine, consistent with and subject to the terms and
conditions of the Plan. 
 (e) “Board” means the Board of Directors of the Company. 

(f) “Change in Control” means (i) a merger or
consolidation of the Company with or into any other corporation or other entity or person, (ii) a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of the Company’s
assets, or (iii) any other transaction, including the sale by the Company of new shares of its capital stock or a transfer of existing shares of capital stock of the Company, the result of which is that a third party that is not an affiliate of
the Company or its stockholders (or a group of third parties not affiliated with the Company or its stockholders) immediately prior to such transaction acquires or holds capital stock of the Company representing a majority of the Company’s
outstanding voting power immediately following such transaction; provided that the following events shall not constitute a “Change in Control”: (A) a transaction (other than a sale of all or substantially all of the Company’s assets)
in which the holders of the voting securities of the Company immediately prior to the merger or consolidation hold, directly or indirectly, at least a majority of the voting securities in the successor corporation or its parent immediately after the
merger or consolidation; (B) a sale, lease, exchange or other transaction in one transaction or a series of related transactions of all or substantially all of the Company’s assets to an affiliate of the Company; (C) an initial public
offering of any of the Company’s securities; (D) a reincorporation of the Company solely to change its jurisdiction; or (E) a transaction undertaken for the primary purpose of creating a holding company that will be owned in
substantially the same proportion by the persons who held the Company’s securities immediately before such transaction. Notwithstanding the foregoing, if a Change in Control would give rise to a payment or settlement event with respect to any
Award that constitutes “nonqualified deferred compensation,” the transaction or event constituting the Change in Control must also constitute a “change in control event” (as defined in Treasury Regulation §1.409A-3(i)(5)) in order to give rise to the payment or settlement event for such Award, to the extent required by Section 409A. 

(g) “Code” means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. 

(h) “Committee” means one or more committees or subcommittees of the Board, which may be comprised of one or
more directors and/or executive officers of the Company, in either case, to the extent permitted in accordance with Applicable Laws. 

  
 14 

 (i) “Common Stock” means the common stock of the Company.

 (j) “Company” means Ideaya Biosciences, Inc., a Delaware corporation, or any successor thereto. Except
where the context otherwise requires, the term “Company” includes any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code and any other business venture
(including, without limitation, joint venture or limited liability company) in which the Company has a significant interest, as determined by the Administrator. 

(k) “Consultant” means any person, including any advisor, engaged by the Company or a parent or
subsidiary of the Company to render services to such entity if: (i) the consultant or adviser renders bona fide services to the Company; (ii) the services rendered by the consultant or advisor are not in
connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities; and (iii) the consultant or advisor is a natural person, or such
other advisor or consultant as is approved by the Administrator. 
 (l) “Designated
Beneficiary” means the beneficiary or beneficiaries designated, in a manner determined by the Administrator, by a Participant to receive amounts due or exercise rights of the Participant in the event of the
Participant’s death or incapacity In the absence of an effective designation by a Participant, “Designated Beneficiary” shall mean the Participant’s estate. 

(m) “Director” means a member of the Board. 

(n) “Disability” means a permanent and total disability within the meaning of Section 22(e)(3) of the Code, as it
may be amended from time to time. 
 (o) “Dividend Equivalents” means a right
granted to a Participant pursuant to Section 6(d)(3) hereof to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock. 

(p) “Employee” means any person, including officers and Directors, employed by the Company (within the meaning of
Section 3401(c) of the Code) or any parent or subsidiary of the Company. 
 (q) “Equity
Restructuring” means, as determined by the Administrator, a non-reciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or
recapitalization through a large, nonrecurring cash dividend, that affects the shares of Common Stock (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share
value of the Common Stock underlying outstanding Awards. 
 (r) “Exchange
Act” means the Securities Exchange Act of 1934, as amended. 
 (s)
“Fair Market Value” means, as of any date, the value of Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, its
Fair Market Value shall be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the first market trading day immediately prior to such date during which a sale occurred, as
reported in The Wall Street Journal or such other source as the Administrator deems reliable; (ii) if the Common Stock is not traded on a stock exchange but is quoted on a national market or
other quotation system, the last sales price on such date, or if no sales occurred on such date, then on the date immediately prior to such date on which sales prices are reported, as reported in The Wall Street Journal or such other source
as the Administrator deems reliable; or (iii) in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined by the Administrator in its sole discretion. 

  
 15 

 (t) “Incentive Stock
Option” means an “incentive stock option” as defined in Section 422 of the Code. 
 (u)
“Non-Qualified Stock Option” means an Option that is not intended to be or otherwise does not qualify as an
Incentive Stock Option. 
 (v) “Option” means an option to purchase Common Stock. 

(w) “Other Stock-Based Awards” means other Awards of
shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property. 

(x) “Participant” means a Service Provider who has been granted an Award under the Plan. 

(y) “Plan” means this 2015 Equity Incentive Plan. 

(z) “Publicly Listed Company” means that the Company or its
successor (i) is required to file periodic reports pursuant to Section 12 of the Exchange Act and (ii) the Common Stock is listed on one or more National Securities Exchanges (within the meaning of the Exchange Act) or is quoted on
NASDAQ or a successor quotation system. 
 (aa) “Restricted Stock” means Common
Stock awarded to a Participant pursuant to Section 6 hereof that is subject to certain vesting conditions and other restrictions. 

(bb) “Restricted Stock Unit” means an unfunded,
unsecured right to receive, on the applicable settlement date, one share of Common Stock or an amount in cash or other consideration determined by the Administrator equal to the value thereof as of such payment date, which right may be subject to
certain vesting conditions and other restrictions. 
 (cc) “Section 409A”
means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. 

(dd) “Securities Act” means the Securities Act of 1933, as amended from time to time. 

(ee) “Service Provider” means an Employee, Consultant or Director. 

(ff) “Termination of Service” means the date the Participant ceases to be a Service Provider. 

* * * * * 

  
 16 

 IDEAYA BIOSCIENCES, INC.  

2015 EQUITY INCENTIVE PLAN 

CALIFORNIA SUPPLEMENT 

This supplement is intended to satisfy the requirements of Section 25102(o) of the California Corporations Code and the regulations
issued thereunder (“Section 25102(o)”). Notwithstanding anything to the contrary contained in the Plan and except as otherwise determined by the Administrator, the provisions set forth in this
supplement shall apply to all Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a “California Participant”) and which are intended to be exempt from registration
in California pursuant to Section 25102(o), and otherwise to the extent required to comply with applicable law (but only to such extent). Definitions in the Plan are applicable to this supplement. 

1. Limitation On Securities Issuable Under Plan. The amount of securities issued
pursuant to the Plan shall not exceed the amounts permitted under Section 260.140.45 of the California code of regulations to the extent applicable. 

2. Additional Limitations For Grants. The terms of all Awards shall comply, to the extent applicable,
with Sections 260.140.41 and 260.140.42 of the California Code of Regulations. 
 3. Additional Requirement To
Provide Information To California Participants. The Company shall provide to each California Participant, not less frequently than annually, copies of annual financial
statements (which need not be audited). The Company shall not be required to provide such statements to key persons whose duties in connection with the company assure their access to equivalent information. In addition, this information requirement
shall not apply to any plan or agreement that complies with all conditions of Rule 701 of the Securities Act (“Rule 701”); provided that for purposes of determining such compliance, any registered
domestic partner shall be considered a “family member” as that term is defined in Rule 701. 
 * * * * * 

  
 CS-1 

 IDEAYA BIOSCIENCES, INC. 

AMENDMENT TO 2015 EQUITY INCENTIVE PLAN 

Pursuant to the authority reserved to the Board of Directors (the “Board”) of Ideaya Biosciences, Inc., a corporation
organized under the laws of State of Delaware (the “Company”), under Section 10(c) of the Company’s 2015 Equity Incentive Plan (the “Plan”), the Board hereby amends the Plan as follows: 

1. Section 4(a) of the Plan be, and hereby is, deleted in its entirety and replaced with the following: 

(a) Number of Shares. Subject to adjustment under Section 8 hereof, Awards may be made under the Plan covering up to 6,355,000
shares of Common Stock (the “Plan Limit”); provided, however, that upon the consummation, pursuant to that certain Series A Preferred Stock Purchase Agreement, dated March 1, 2016, by and among the Company and the
purchasers party thereto (the “Purchase Agreement”), of each Closing following the First Tranche Closing, the Plan Limit shall automatically increase (such increase, the “Plan Limit Increase”) to that
number of shares of Common Stock equal to the product of .175 multiplied by the Company’s Fully-Diluted Capitalization (as defined below) as of immediately following such Closing, rounded down to the nearest whole share. If any Award expires or
lapses or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below the
original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the
grant of Awards under the Plan. Further, shares of Common Stock delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable
tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall be added to the number of shares of Common Stock available for the grant of Awards under the
Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized
but unissued shares, shares purchased on the open market or treasury shares. As used herein, “Fully-Diluted Capitalization” means the sum of (A) all shares of Common Stock actually outstanding, (B) all shares of
Common Stock issuable upon exercise, conversion or exchange of all Convertible Securities (as defined in the Company’s Amended and Restated Certificate of Incorporation, as it may be amended from time to time) then-outstanding (including those
issued under the Plan), and (C) all shares authorized for issuance under the Plan after giving effect to the Plan Limit Increase, exclusive of any shares of Common Stock included pursuant to clause (A) and (B) of this sentence. 

 I hereby certify that the foregoing Amendment to the Plan was duly adopted by the Board
effective as of February 27, 2016. 
 I hereby further certify that the foregoing Amendment to the Plan was duly adopted by the
Company’s stockholders effective as of February 27, 2016. 
 Executed on this 29th day of February, 2016. 

 

	
	
	/s/ Mark V. Roeder
	Mark V. Roeder, Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]